Orthogenics AS is a biotechnology company located in the Science Park of Tromsø, Norway. The company is focusing on research and product development within cartilage-related diseases, primarily osteoarthritis (OA).
Orthogenics primarily aims to provide easy-to-use diagnostics for early detection of OA, based on the company’s patented discoveries. Orthogenics have ambitions to offer the first effective therapy against OA, together with pharmaceutical partners.
The company is based on results from a research collaboration between the University of Tromsø and the University Hospital of Northern Norway, and was founded in 1999 by three Professors and Medical doctors at these institutions.
Today the company engages 6 employees, in addition to the founders, the executive board of directors and the scientific advisory board.
Orthogenics has in the last years received two major grants from the Norwegian Research Council, and enjoys a good relationship with local, regional and national investors. This enables the company to push forward with a very ambitious scientific program.
The current best practice for diagnosing OA is a multi factorial exercise needing highly competent personnel, and involving several types of complicated imaging instruments. The procedure is complicated, costly and slow.
Orthogenics’ primary products will be easy-to-use, quick and cost effective tests that can diagnose OA, and separate the known patient population into treatable and non-treatable groups.
The company is currently developing tests for laboratory services and diagnostic kit commercialization.
There is currently no treatment that actually prevents osteoarthritis, or reverses or blocks the disease process once it begins. Present treatments only relieve the symptoms.
Orthogenics’ aims to develop effective treatments for early OA patients together with pharma partners. Specific treatment will be developed based on Orthogenics unique understanding of the molecular, inflammatory processes in OA-joints.